Trials
2 active
9 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class”In the company’s words, NCT07508787 on ClinicalTrials.gov
- Main trialPhase 2
- “The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.”In the company’s words, NCT06019507 on ClinicalTrials.gov
- Other names
- TCD601
Other drugs for Liver Transplantation
- FosmanogepixBasilea Pharmaceutica · Phase 3
- PosaconazoleMerck & Co. · Phase 2
- OlorofimF2G Biotech GmbH · Phase 2
Coming up1
- 28 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Jun 2026 | A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation | |
| Phase 2Recruiting | 28 Mar 2028 | A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant | |
| Phase 2Completed | 3 Oct 2023 | A Dose Escalation Study in de Novo Renal Transplantation | |
| Phase 2Terminated | 11 Dec 2024 | A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation | |
| Phase 2Terminated | 24 Jul 2025 | A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients | |
| Phase 2Terminated | 30 Oct 2025 | A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA) | |
| Phase 2Terminated | 17 Feb 2026 | A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE) | |
| Phase 2Completed | 10 Apr 2026 | A Study of TCD601 in de Novo Renal Transplant Recipients | |
| Phase 1Terminated | 2 Jul 2026 | A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026